Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients

• Status: Not yet recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The rationale of the use of tramadol for COVID-19 patients is attributed to its anti-inflammatory, hypocagulatory, antioxidant, cardio-protective, analgesic, antitussive, bactericidal and antidepressant effect.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Tramadol

Criteria

Inclusion Criteria:

• Newly diagnosed symptomatic COVID-19 patients with mild to moderate respiratory manifestations, adults (18-65 Years old), and both sexes.

Exclusion Criteria:

• Patients with abnormal liver function (ALT, AST), chronic kidney disease or dialysis (CrCl< 30 ml/min)

• Pregnant women or women who are breastfeeding

• Immunocompromised patients taking medication upon screening

• Subjects with comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, malignancy

• Patients having allergy to Hydroxychloroquine and/or Nitazoxanide

• Patients with contraindication towards the study medication including retinopathy, G6PD deficiency and QT prolongation.